- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Tahir Amin: Successful Challenges to Drug Patents
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses successes in drug patent challenges.
Transcript:
Can you share some of your success stories in challenging patents and lowering the cost of drugs for patients?
A lot of our work happened in India in the initial years on a number of first-line and second-line HIV drugs, [anti-retrovirals, ARVs]. We were successful in challenging those patents so Indian engineering companies could continue to export them to African countries. For example, India supplies 80% of generic HIV medicines to African countries, so we were able to keep that pipeline open.
In a number of cases our cases have actually lent themselves to creating leverage over the pharmaceutical companies in such that they’ve struck licensing deals. For example, we helped some of our colleagues in Ukraine and now Ukraine is included in that license as a result of that challenge.
The knock-on effect is to try and take some of the power away from the pharmaceutical companies, where you threaten the very rights that allow them to have all that power. Really, it’s about balancing the interests and making sure the system is working for both sides.
Unfortunately, I feel we’ve titled far too much in the favor of the pharmaceutical companies, and that’s why we see the problems we have today where drug prices are going up astronomically and, unfortunately, no one is able to really do anything about it. That’s why we feel our intervention is critical in terms of trying to redress some of those imbalances.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
